| Document Date: 2013-10-31 09:37:27
Open Document File Size: 331,12 KBShare Result on Facebook
City Bellinzona / / Company Humabs BioMed SA / PhD / / Country Switzerland / / Currency USD / / / Facility Switzerland’s Institute / / IndustryTerm immune systems / platform technology / pharmaceutical / / MedicalCondition human and animal influenza viruses / cancer / MPV infection / HIV / pulmonary infections / disease / infectious and inflammatory diseases / lower respiratory tract infection / rabies / severe lower respiratory tract infections / influenza A / acute infections / respiratory infections / serious infections / hepatitis B / bacterial infection / RSV-associated severe bronchiolitis / infectious diseases / severe infections / neurodegenerative diseases / illness / influenza / dengue viruses / human disease / influenza B / autoimmune diseases / / Organization Switzerland’s Institute for Research / / Person Antonio Lanzavecchia / Alcide Barberis / Davide Corti / / / Position CEO / President / president and CEO / head of antibody discovery / first author / scientific founder / / Product Synagis / / Technology antibodies / platform technology / cloning / / URL www.humabs.c / /
SocialTag |
ADVERTISEMENT FEATURE HUMABS BioMed www.humabs.c om The antibodies of winners make the difference